Erasca, Inc. (ERAS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$16.19-0.43%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ERAS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -22.9% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has been missing across recent quarters and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ERAS — litigation filed
Dated 2026-08-24
Other Events. On August 24, 2026, Erasca, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation (“FTD”) to ERAS-0015 for the treatment of patients with metastatic pancreatic adenocarcinoma. FTD is intended to facilitate development and expedite the review of therapies for serious conditions with unmet medical needs. Designated programs may benefit from more frequent interactions with the FDA and, if relevant criteria are met, may…
Why it matters: Initial data on ERAS-4001 will show if it can compete in the KRAS space.
Supportive ifData on safety and effectiveness for ERAS-4001 will come in H2 2026.
Worry ifData is delayed beyond H2 2026 or shows poor safety and efficacy.
Why it matters: Combination data will show if ERAS-0015 can improve treatment when used with other therapies. This could make it a key treatment.
Supportive ifCombination data shows it works better than using one treatment alone.
Worry ifCombination data shows no real gain compared to using one treatment alone.
Why it matters: This data will show how well ERAS-0015 works in patients with RAS-driven cancers. Positive results could boost confidence in the drug's potential.
Supportive ifEarly Phase 1 data shows strong responses in patients with RAS mutations.
Worry ifData shows that ERAS-0015 has safety issues. This raises concerns about its effectiveness.
Why it matters: Data from the ERAS-0015 trial will show how well it treats RAS-driven cancers. Good results could help investors feel more confident.
Supportive ifNew data shows good response rates for monotherapy in KRAS G12X lung or pancreatic cancer.
Worry ifMonotherapy data shows weak or no response rates in KRAS G12X lung or pancreatic cancer.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$235 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $564 loss on $10,000 · 5.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,946 loss on $10,000 · 59.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: New data could show how effective ERAS-0015 is in treating tumors. Positive results may boost investor confidence.
Supportive ifA press release showing improved response rates in patients treated with ERAS-0015.
Worry ifData shows no big change in patient outcomes. Safety concerns still exist.
Why it matters: Advancing trials is key to the company's strategy. Delays could hurt investor confidence.
Supportive ifThey announced good news about trial milestones. They also shared updates on patient recruitment.
Worry ifFurther delays or setbacks in trial progress are reported.
Why it matters: Lawsuit outcomes could affect ERAS-0015's future. A loss for Erasca could hurt its market.
Worry ifThe lawsuit ended well for Erasca. They can keep working on ERAS-0015.
Less concerning ifA court ruled against Erasca. This limits their ability to develop ERAS-0015.
Why it matters: Earnings results will show if the company is on track to fund operations into 2028. A miss could raise concerns.
Worry ifQ2 earnings report shows revenue growth or meets expectations after the Q1 earnings miss.
Less concerning ifQ2 earnings report shows another miss or declining revenue.